This clinical rigor ensures physiological safety and medical accountability for our discerning patients commuting from Gachibowli, Hitech City, and beyond in Hyderabad
Autoimmune Thyroid Disorders and Gluten-Induced Dysbiosis Previous studies have reported that maintaining gut health has systemic impacts on improving autoimmune disorder conditions (27)
Figure 2 The gut microbiota constantly communicates with vital organ systems of the host, such as the brain (Dinan and Cryan, 2017), kidney (Bartochowski et al., 2022), autonomic nervous system (ANS) (Bercik et al., 2011), and immune system (Rooks and Garrett, 2016)
GLP-1 (Glucagon-like Peptide-1) is a natural incretin hormone that: Stimulates insulin secretion (when glucose is high) Suppresses glucagon release Slows gastric emptying Increases satiety reducing food intake Why GLP-1 Therapy Stands Out Glycemic Control Lowers HbA1c by ~11.5% with minimal hypoglycemia risk Weight Loss 515 kg depending on drug/dose (semaglutide leads the way) Cardiovascular Protection Reduced major CV events (MACE) in trials like LEADER, SUSTAIN, REWIND Renal Protection Slows progression of diabetic kidney disease Convenience Available as daily or weekly injections and even oral semaglutide Key Clinical Trials LEADER (Liraglutide) CV mortality & MACE SUSTAIN-6 (Semaglutide) CV events & strong weight loss REWIND (Dulaglutide) CV protection even in lower-risk populations STEP Trials (Semaglutide) Double-digit weight reduction in obesity The Bigger Picture GLP-1 therapy goes beyond insulin and beyond diabetes
GLP-1 medications also suppress your appetite and promote a feeling of satiety (fullness) more quickly and for longer periods of time via delayed stomach emptying (gastroparesis)
